...
首页> 外文期刊>Journal of cellular physiology. >Aurora kinase inhibitor restrains STAT5-activated leukemic cell proliferation by inducing mitochondrial impairment
【24h】

Aurora kinase inhibitor restrains STAT5-activated leukemic cell proliferation by inducing mitochondrial impairment

机译:极光激酶抑制剂抑制STAT5-activated通过诱导白血病细胞增殖线粒体损伤

获取原文
获取原文并翻译 | 示例
           

摘要

Current chemotherapy regimens on acute myeloid leukemia (AML) still have some drawbacks, such as intolerance and drug resistance, which calls need for the development of targeted therapy. Signal transducer and activator of transcription 5 (STAT5) is often overexpressed or abnormally activated in leukemia and involved in cell self-renewal, proliferation, and stress adaptation. Overexpressed Aurora A (AURKA) is associated with poor prognosis in tumors, and inhibitors against AURKA are already in clinical trials. However, it has rarely been reported whether AURKA inhibitors restrain STAT5-activated leukemia cells. In this study, we constructed STAT5 constitutively activated (cS5) cells and found that STAT5 promoted cell proliferation and colony formation. Moreover, cS5 cells showed elevated reactive oxygen species (ROS) and adenosine triphosphate (ATP) levels, which indicated higher mitochondrial metabolism in cS5 cells. A novel AURKA inhibitor AKI604 was synthesized and showed significant inhibitory effects to the proliferation and colony formation in both STAT5 constitutively activated and nonactivated AML cells. AKI604 induced mitochondrial impairment, leading to the disruption of mitochondrial membrane potential and the elevation of ROS as well as cellular calcium (Ca2+) levels. AKI604 could also decline basal oxygen consumption rate and ATP biosynthesis, indicating the damage of oxidative phosphorylation. Furthermore, AKI604 exhibited significant antitumor effect in the HL-60 cS5 xenograft model of the BALB/c nude mice without an obvious influence on mice body weight and other healthy indicators. This study suggested that AKI604 was a potential strategy to overcome STAT5-induced leukemic proliferation in AML treatment by inducing mitochondrial impairment.
机译:目前化疗方案在急性骨髓白血病(AML)仍有一些缺点,比如不宽容和耐药性,调用所需要的靶向治疗的发展。传感器和转录激活5(STAT5)往往是过表达或异常激活细胞白血病和参与自我更新、增殖和压力适应。与肿瘤预后不良有关抑制剂对AURKA已经在临床试用是否AURKA抑制剂抑制STAT5-activated白血病细胞。STAT5持续激活(cS5)细胞发现STAT5促进细胞增殖集落形成。升高活性氧(ROS)三磷酸腺苷(ATP)含量表明线粒体代谢cS5高细胞。合成和显示显著的抑制影响扩散和集落形成STAT5持续激活和未激活的AML细胞。线粒体损伤,导致线粒体膜电位的影响ROS的高程以及细胞钙(Ca2 +)的水平。基底耗氧率和ATP生物合成,表明氧化的伤害磷酸化。重要的抗肿瘤效应HL-60 cS5异种移植的BALB / c裸小鼠模型对小鼠体重和一个明显的影响其他健康指标。AKI604是一个潜在的策略来克服AML STAT5-induced白血病细胞增殖治疗诱导线粒体损伤。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号